Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/16/2026

1. SABR
2. USO
3. SPY
4. JPM
5. ELBM
6. QQQ
7. BBNX
8. EXE
9. NVDA
10. VTRS

Go back to Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1136.11 --0 (-0%)
Previous Close $1136.11    52 Week High $88.16 
Open $1136.11    52 Week Low $67.88 
Day High $1136.11    P/E 262.99 
Day Low $1136.11    EPS $4.32 
Volume 3,527